Skip to content
Login
Search:
CROI Conference
CROI ConferenceCROI Conference
  • About CROI
    • CROI 2027 Important Dates
    • CROI Foundation
    • Scientific Program Committee and Community Liaison Subcommittee
    • Funding and Grant Support
    • IAS-USA
    • Policies, Website, and Copyrights
    • Illustrations of HIV, HCV, and SARS-CoV-2 Viruses
    • Contact Us
  • Abstracts
    • CROI Abstract Categories
    • Abstract Guidelines and Submission
    • Assignment of Abstract Copyright to CROI
    • People-First Language and the Use of Appropriate Terminology
  • Presenters
    • Invited Presenters and Moderators
    • Letter Of Invitation (For Visa And Other Purposes)
  • Attendees
    • Who Can Attend
    • Letter Of Invitation (For Visa And Other Purposes)
    • Affiliated and Proximate Activities
    • Frequently Asked Questions
  • Scholarships
    • New Researcher Scholarship
    • International Researcher Scholarship
    • Community Educator and Mentor Scholarships
  • Program
    • CROI 2027 Program
    • Our Voices
    • Media
    • Embargo Policies And Press Release Policies
    • Resources From Prior Years
    • Webcasts
    • Abstracts and ePoster Archive
    • CROI Issues of TAM
  • About CROI
    • CROI 2026 Preliminary Important Dates and Deadlines
    • CROI Foundation
    • Scientific Program Committee and Community Liaison Subcommittee
    • Funding and Grant Support
    • IAS-USA
    • Policies, Website, and Copyrights
    • Illustrations of HIV, HCV, and SARS-CoV-2 Viruses
    • Contact Us
  • Abstracts
    • Abstract Guidelines and Submission
    • CROI Abstract Categories
    • Assignment of Abstract Copyright to CROI
    • People-First Language and the Use of Appropriate Terminology
  • Presenters
    • Invited Presenters and Moderators
    • Oral Abstract Presentation Guidelines
    • Poster Presentation Guidelines
    • Themed Discussion Guidelines
    • Plain Language Summaries: A Mile-High View at CROI 2026
    • People-First Language and the Use of Appropriate Terminology
    • Letter Of Invitation (For Visa And Other Purposes)
  • Attendees
    • Registration
    • Who Can Attend
    • Media Accreditation and Registration
    • Affiliated and Proximate Activities
    • Frequently Asked Questions
  • Scholarships
    • New Researcher Scholarship
    • International Researcher Scholarship
    • Community Educator and Mentor Scholarships
    • Scholarship Travel
  • Program
    • CROI 2027 Program
    • CROI 2026 Resources
    • Our Voices
    • Media
    • Resources From Prior Years
    • Webcasts
    • Abstracts and ePoster Archive
    • CROI Issues of TAM
  • CROI 2027 Important Dates

Search Results for: node/PEP: Remember Me?

Etravirine/Rilpivirine-Specific Mutations Selected by EFV and NVP in Kenyan Patients Failing ART

By Enthusiast Inc MDSeptember 29, 2014

…Kenyan patients with non-B subtypes failing first line therapy with neviripine or efavirenz. Methodology: RV288 is a multi-center PEPFAR Basic Program Evaluation that is being conducted in Kenya, Tanzania, Uganda…

BINDING SIGNATURES AND CROSS-REACTIVITY IN THE SARS-CoV-2 IMMUNE RESPONSE

By Jimmy He PharmD, DScApril 22, 2021

…phage display library composed of 39 amino acid peptides covering the complete genomes of SARS-CoV-2 and the six other CoVs known to infect humans. Using samples from patients with confirmed…

Drug Resistance After 2nd-Line Failure Can Be Managed Using WHO-Recommended Regimens in Nigeria

By Enthusiast Inc MDSeptember 29, 2014

…of treatment options to WHO recommended treatment regimens at two IHVN PEPFAR supported sites in Abuja. Methodology: Plasma samples from patients who failed LPV/r and ATV/r- based second-line regimens from…

402 – Heterogeneous Antiretroviral (ARV) Class Effects on Tissue HIV Reservoirs

By Jimmy He PharmD, DScMarch 31, 2026

…regimen) × TE interaction on reservoir metrics adjusting for clinical/ART history covariates. Observed margins (real regimen mix) and counterfactual margins (covariates set to isolate each ARV class and assess pure…

Reduction of SIV-Mediated Immune Activation by p38 MAPK In Vivo Inhibition

By Enthusiast Inc MDFebruary 16, 2016

…of CD4+/IL22+ and CD4+/IL-17+ T-cells in PBMC, rectal and lymph node mononuclear cells and of central memory CD4+ T cells in blood was also observed in the ART+p38 inhibitor group…

WIDE ANATOMIC DISTRIBUTION OF HIV-INFECTED CELLS IN INDIVIDUALS WITH COMORBID CANCER

By Jimmy He PharmD, DScApril 28, 2020

…for primary effusion lymphoma (PEL) or metastatic adenocarcinoma; both were on effective ART with HIV RNA < 50 c/ml. Tissue samples (lung, mediastinal lymph node, spleen, testes, liver, and neoplastic…

SPECT/CT IMAGING OF CD4-POOL SUGGESTS A NOVEL CORRELATE OF BENIGN DISEASE PROGRESSION

By Enthusiast Inc MDMarch 5, 2018

…(median nadir:743 cells/µl; median SIV RNA set-point:3,760 copies/ml. 4/5 had a protective haplotype). The remaining five showed features of CP with CD4 T counts <500 (median nadir:177 cells/µl; median SIV-RNA…

A PHASE I CLINICAL TRIAL WITH A CONSENSUS SEQUENCE-BASED NATIVE-LIKE HIV-1 Env TRIMER

By Jimmy He PharmD, DScApril 4, 2022

…aimed to increase antibody responses and levels of somatic hypermutation. Safety information is solicited throughout a period of 18 months. Serological assays are performed, as well as lymph node fine…

EXPANSION AND EXTENSIVE RECIRCULATION OF HIV-INFECTED CELLS IN MULTIPLE ORGANS

By Jimmy He PharmD, DScApril 4, 2022

…1). Participant #2 proviruses often contained large deletions (88% of all defects), whereas viral genomes from participant #1 displayed equally hypermutations (39%) or large deletions (42%). Intact HIV genomes represented…

Identical Sequence Expansions Are Predominantly Found in Effector Memory T Cells

By Enthusiast Inc MDFebruary 27, 2015

…sequencing, we isolated intracellular HIV-1 genomes derived from defined subsets of CD4+ T cells (central (CM)-, transitional (TM)-, and effector (EM)-memory) from peripheral blood and lymph node tissue. Samples were…

←1
234567891011121314151617181920212223242526272829303132333435363738394041
…4243444546…
474849505152535455565758596061626364656667686970717273747576777879808182
83→
Copyright © 2026 CROI Foundation/IAS-USA. All Rights Reserved.
Website by Enthusiast, Inc.
  • About CROI
  • Presenters
  • Abstracts
  • Scholarships
  • Program
Footer Menu
Go to Top